Gestational diabetes mellitus management with oral hypoglycemic agents.

Autor: Ryu RJ; Department of Pharmacy, University of Washington, 1959 NE Pacific St, H-375 Health Sciences Center, Box 357630, Seattle, WA 98195-7630., Hays KE; Department of Pharmacy, University of Washington, 1959 NE Pacific St, H-375 Health Sciences Center, Box 357630, Seattle, WA 98195-7630., Hebert MF; Department of Pharmacy, University of Washington, 1959 NE Pacific St, H-375 Health Sciences Center, Box 357630, Seattle, WA 98195-7630; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA. Electronic address: mhebert@u.washington.edu.
Jazyk: angličtina
Zdroj: Seminars in perinatology [Semin Perinatol] 2014 Dec; Vol. 38 (8), pp. 508-15. Date of Electronic Publication: 2014 Oct 12.
DOI: 10.1053/j.semperi.2014.08.012
Abstrakt: Oral hypoglycemic agents such as glyburide (second-generation sulfonylurea) and metformin (biguanide) are attractive alternatives to insulin due to lower cost, ease of administration, and better patient adherence. The majority of evidence from retrospective and prospective studies suggests comparable efficacy and safety of oral hypoglycemic agents such as glyburide and metformin as compared to insulin when used in the treatment of women with gestational diabetes mellitus (GDM). Glyburide and metformin have altered pharmacokinetics during pregnancy and both agents cross the placenta. In this article, we review the efficacy, safety, and dosage of oral hypoglycemic agents for the treatment of gestational diabetes mellitus. Additional research is needed to evaluate optimal dosage for glyburide and metformin during pregnancy. Comparative studies evaluating the effects of glyburide and metformin on long-term maternal and fetal outcomes are also needed.
(Copyright © 2014 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: